Pacira BioSciences (PCRX) Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Which has preferable earnings & valuation, SUPN or PCRX?

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$607.52M	2.71	$1.32M	N/A	N/A
Pacira BioSciences	$674.98M	1.81	$41.96M	$0.81	32.51

Is SUPN or PCRX more profitable?

Pacira BioSciences has a net margin of 6.22% compared to Pacira BioSciences' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 12.81% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	0.22%	0.14%	0.09%
Pacira BioSciences	6.22%	12.81%	6.80%

Which has more volatility and risk, SUPN or PCRX?

Supernus Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Does the MarketBeat Community favor SUPN or PCRX?

Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.

Company	Underperform	Outperform
Supernus Pharmaceuticals	Outperform Votes 471 73.25%	Underperform Votes 172 26.75%
Pacira BioSciences	Outperform Votes 807 71.73%	Underperform Votes 318 28.27%

Does the media refer more to SUPN or PCRX?

In the previous week, Pacira BioSciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Pacira BioSciences and 3 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.84 beat Supernus Pharmaceuticals' score of 0.83 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer SUPN or PCRX?

Supernus Pharmaceuticals currently has a consensus price target of $41.00, suggesting a potential upside of 36.35%. Pacira BioSciences has a consensus price target of $49.50, suggesting a potential upside of 88.00%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pacira BioSciences	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of SUPN or PCRX?

99.7% of Pacira BioSciences shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Pacira BioSciences beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.